Who is sponsoring NCT04124861?

NCT04124861 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT04124861?

Interventions in NCT04124861: Drug free, IS monotherapy and GC combined with IS.

What condition does NCT04124861 study?

NCT04124861 studies Autoimmune Diseases.

Is NCT04124861 still recruiting?

NCT04124861 is currently status unknown. Last updated 7 February 2022.

Last reviewed 2022-02-07 · How we verify

NCT04124861

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Withdraw Drug in Stable IgG4-Related Disease

Status unknown NA Last updated 7 February 2022

What this trial tests

NA trial testing Drug free, IS monotherapy and GC combined with IS in Autoimmune Diseases in 138 participants. Status unknown.

Timeline

23 June 2020

Primary endpoint
30 December 2022

30 June 2023

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	138
Start date	23 June 2020
Primary completion	30 December 2022
Estimated completion	30 June 2023
Sites	1 location across China

Drugs / interventions tested

Drug free, IS monotherapy and GC combined with IS — full drug profile →

Conditions studied

Autoimmune Diseases — all drugs for Autoimmune Diseases →

Sponsor

Peking Union Medical College Hospital

Who can join

Adults 18 to 70, any sex, with Autoimmune Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation and prediction of relapse risk after glucocorticoid or immunosuppressant withdrawal in patients with stable IgG4 related disease: a prospective cohort study from china.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Withdrawal of immunosuppressants and low-dose steroids in patients with stable IgG4-RD (WInS IgG4-RD): an investigator-initiated, multicentre, open-label, randomised controlled trial.
Peng L, Nie Y, Zhou J, Wu L, et al · · 2024 · cited 24× · PMID 38216319 · DOI 10.1136/ard-2023-224487

Verify or expand the search:

Other recruiting trials for Autoimmune Diseases

Currently open trials in the same condition.

NCT06948110 — Deciphering the Genetic Architecture of Autoimmune Diseases · recruiting
NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
NCT07408336 — Clinical Study of AFN50 Injection in the Autoimmune Diseases · EARLY_PHASE1 · recruiting
NCT07283315 — Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paedia · EARLY_PHASE1 · recruiting
NCT07221890 — A Trial of Academic Detailing to Promote Prescribing of Biosimilars · NA · active not recruiting

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04124861 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 7 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04124861.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing